Animas Corporation made it known to the world that the FDA has finally approved the application of Animas Vibe® Insulin Pump and Continuous Glucose Monitoring (CGM) System. The device is effective when it comes to the management of diabetes in kids and teens, ages 2 to 17. First to have Dexcom G4® PLATINUM CGM technology, the system comes as a boon for many pediatric patients. Furthermore, the new system enables patients and their family members or caregivers to monitor the glucose data and administer the correct insulin dose from the pump. This aids in fine -tuning the delivery of insulin and help manage diabetes.
There has been an increasing demand for monitoring systems, that can offer a complete glucose picture. The demand for managing diabetes in kids as the symptoms in youth is not always linked with low or high blood sugars.
To date, several clinical studies have revealed the value of such insulin pump therapy. Studies unveil that the efficacy of these pumps when compared to the frequently used multiple daily injections are high. Thus, the new insight into the trend would help kids with type 1 diabetes. These systems also enable parents to stay informed and take smarter decisions when it comes to fulfilling the insulin needs.
Eyeing the recent developments in the continuous glucose monitoring systems, Big Market Research has added a market research report titled “World Continuous Glucose Monitoring Systems - Market Opportunities and Forecasts, 2014 – 2021.” As per the report the industry is expected to generate about $2.9 billion in sales by 2021. Research analysts also indicate that the market is likely to register a CAGR of 31.4 percent during the forecast period 2014 – 2021. This clearly indicates that the continuous glucose monitoring system by Animas has a bright future. Regions including North America, Europe, Asia -Pacific and LAMEA would experience tremendous growth.